Founded in January 2015 by a distinguished team of scientists, Creative Biosciences is a leading biotechnology company dedicated to advancing noninvasive cancer testing. Our flagship product, Colosafe, is a stool DNA test designed for the early detection of colorectal cancer. In addition to Colosafe, we specialize in the development, manufacturing, and commercialization of automation equipment that supports Colosafe testing and related technologies. Lunsafe is another noninvasive DNA test for early detection of lung cancer, which was just approved by NMPA on May 29, 2025.

Headquartered in Guangzhou China, Creative Biosciences is equipped with cutting-edge R&D laboratories, GMP-certified manufacturing facilities, and a modern corporate campus, covering a combined area of 51,000 square meters. To strengthen our global footprint, we have established subsidiaries in Hong Kong, the United States, and Germany. This infrastructure forms an extensive and efficient business development and testing service network both domestically and internationally.

In March 2020, we acquired Helixgen, significantly enhancing our research and development capacity. Creative Biosciences holds numerous proprietary intellectual property rights and continues to push the boundaries of innovation with world-class R&D capabilities aimed at driving the next generation of diagnostic solutions.

Beyond Colosafe and Lunsafe, we are actively expanding our product pipeline to include noninvasive early detection kits for bladder, cervical, and liver cancer, as well as Point-of-Care Testing (POCT) solutions—reinforcing our commitment to transforming cancer diagnostics through innovation. Guided by the mantra of "Human health, my mission," we strive to achieve breakthroughs and progress in the early cancer detection, early treatment, and prognosis monitoring, putting the benefit of the people in our hearts.